Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-10-16
2007-10-16
Brumback, Brenda (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387300, C530S388100, C530S388150, C435S069100, C435S320100
Reexamination Certificate
active
10213181
ABSTRACT:
The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.
REFERENCES:
patent: WO98/58061 (1998-12-01), None
patent: WO99/55868 (1999-11-01), None
patent: WO 01/53455 (2001-07-01), None
patent: WO 01/98471 (2001-12-01), None
Campo et al. Biological Trace Element Research, vol. 79, pp. 15-22, 2001.
Barry D. Kahan, Current Opinion in Immunology, vol. 4, pp. 553-560, 1992.
Nishioka et al. Journal of Leukocyte Biology, vol. 73, pp. 621-629, 2003.
Piccotti et al, Transplantation, vol. 67, pp. 1453-1460, 1999.
Gretchen Vogel, Science vol. 311, pp. 1688-1689, Mar. 2006.
James A. Wells, Biochemistry, vol. 29, No. 37, pp. 8509-8517, Sep. 1990.
Alderson et al., “Molecular and Biological Characterization of Human 4-1BB and Its Ligand.”European Journal of Immunology. 24(9) :2219-2227 (Sep. 1994).
Bolton, C. , “Recent Advances in the Pharmacological Control of Experimental Allergic Encephalomyelitis (EAE) and the Implications for Multiple Sclerosis Treatment.”Multiple Sclerosis. 1:143-149 (1995).
Chambers and Allison., “Co-Stimulation in T Cell Responses.”Current Opinion in Immunology. 9(3) :396-404 (Jun. 1997).
Coligan et al, eds. , “Proliferative Assays for T Cell Function”Current Protocols in Immunology, John Wiley & Sons, Inc., Chapter 3.12, vol. 1 (1994).
Coligan et al., eds.Current Protocols in Immunology., New York:John Wiley & Sons, Inc., Chapter 15.1, 15.2, (1994).
Coligan et al., eds., “Delayed-Type Hypersensitivity.”Current Protocols in Immunology., New York:John Wiley & Sons, Inc., Chapter 4.5, (1994).
Grabbe and Schwarz., “Immunoregulatory Mechanisms Involved in Elicitation of Allergic Contact Hypersensitivity.”Immun. Today. 19(1) :37-44 (1998).
Hellstrom and Hellstrom., “T Cell Immunity to Tumor Antigens.”Critical Reviews in Immunology. 18(1-2) :1-6 (1998).
Issekutz et al., “Treatment of Established Adjuvant Arthritis in Rats with Monoclonal Antibody to CD18 and Very Late Activation Antigen-4 Integrins Suppresses Neutrophil and T-Lymphocyte Migration to the Joints and Improves Clinical Disease.”Immunology. 88:569-576 (1996).
Jenkins, M., “The Ups and Downs of T cell Costimulation.”Immunity, 1(6) :443-446 (Sep. 1994).
June et al., “The B7 and CD28 Receptor Families,”Immunology Today. 15(7) :321-331 (Jul. 1994).
Linsley and Ledbetter., “The Role of the CD28 Receptor During T Cell Responses to Antigen.”Annu. Rev. Immunol. 11:191-212 (1993).
Schwartz, R., “Costimulation of T Lymphocytes: The Role of CD28, CTLA-4, and B7/BB1 in Interleukin-2 Production and Immunotherapy.”Cell. 71(7) :1065-1068 (Dec. 24, 1992).
Tanabe et al., “Combined Immunosuppressive Therapy with Low Dose FK506 and Antimetabolites in Rat Allogeneic Heart Transplantation.”Transplantation, 58(1) :23-27 (1994).
Tinubu et al., “Humanized Antibody Directed to the IL-2 Receptor β-Chain Prolongs Primate Cardiac Allograft Survival.”J. Immunol. 153:4330-4338 (1994).
Walunas et al., “CTLA-4 Can Function as a Negative Regulator of T Cell Activation.”Immunity. 1(5) :405-413 (Aug. 1994).
Wolyniec et al., “Reduction of Antigen-Induced Airway Hyperreactivity and Eosinophilia in ICAM-1-Deficient Mice.”Am. J. Respir. Cell Mol. Biol. 18:777-785 (1998).
Buckley et al., “Plasma Cell Membrane Glycoprotein PC-1”Journal of Biological Chemistry265(29) :17506-17511 (1990).
Clark et al., “The Secreted Protein Discovery Initiative (SPDI) , a Large-Scale Effort to Identify Novel Human Secreted and Transmembranes Proteins: A Bioinformatics Assessment”Genome Research, XP001189293, Cold Spring Harbor Laboratory Press vol. 13:2265-2270 (2003).
Database EMBL, “wa15g01.x1 NCI—CGAP—KidII Homo sapiens cDNA clone IMAGE:2298192 3' similar to contains TAR1.t2 TAR1 repetitive element : mRNA sequence.”NCI-CGAP, Database accession No. AI640575 vol. XP002297353 (Apr. 29, 1999).
Database NCBI; Clark et al., “Homo sapiens clone DNA108700 RGLA3077 (UNQ3077) mRNA, complete cds.”Database accession No. AY358622, XP002297354 (Oct. 3, 2003).
Duan et al., “Identification of Human Intestinal Alkaline Sphingomyelinase as a Novel Ecto-enzyme Related to the Nucleotide Phosphodiesterase Family”Journal of Biological Chemistry278(40) :38528-38536 (2003).
Jin-Hua et al., “Molecular Cloning and Chromosomal Localization of PD-Iβ (PDNP3), a New Member of the Human Phosphodiesterase I Genes”Genomics, XP004434160, San Diego:Academic Press vol. 45(2) :412-415 (Oct 15, 1997).
Dziarski, Roman, “Enhancement of Mixed Leukocyte Reaction and Cytotoxic Antitumor Responses by Heparin,”Journal of Immunology, vol. 143, No. 1, pp. 356-365 (Jul. 1989).
McDyer, et al., “Patients with Multidrug-Resistant Tuberculosis with Low CD4+ T Cell Counts Have Impaired Th1 Responses,”The Journal of Immunology, vol. 158, pp. 492-500 (1997).
McElrath, et al., “Cutaneous Response to Recombinant Interleukin 2 in Human Immunodeficiency Virus 1-Seropositive Individuals,”Proc. Natl. Acad. Sci, USA, vol. 87, pp. 5783-5787 (1990).
Tyring, S., “Imiquimod Applied Topically: A Novel Response Modifier,”Skin Therapy Letter, 6(6):1-4 (Mar. 2001).
Zaki, et al., “Synergistic Enhancement of Cell-Mediated Immunity by Interleukin-12 Plus Interleukin-2: Basis for therapy of Cutaneous T Cell Lumphoma,”J. Invest. Dermatol., vol. 118, No. 2, pp. 366-371 ( Feb. 2002).
Goddard Audrey
Godowski Paul J.
Gurney Austin L.
Tumas Daniel
Watanabe Colin K.
Barnes Elizabeth M.
Brumback Brenda
Dreger Ginger R.
Genentech Inc.
Hamud Fozia
LandOfFree
Compositions and methods for the treatment of immune related... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment of immune related..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment of immune related... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3857586